SBRT has equivalent toxicity with 5 treatments and 12 treatments: an update

We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …

SBRT vs. moderate hypofractionation: same or better quality of life?

In several randomized clinical trials of external beam treatment of primary prostate cancer, we have seen that moderately hypofractionated intensity-modulated radiation therapy (HypoIMRT), accomplished in 12 to 26 treatments or fractions, is no worse than conventionally fractionated IMRT treatment (in 40 to 44 fractions). … READ MORE …

Toxicity equal for SBRT and conventional external beam radiation (3D-CRT)

There has been some question as to whether the toxicity of delivering very high doses of external beam radiation per treatment (or fraction) in fewer fractions (called “extreme hypofractionation” or SBRT) would be high compared to conventional dose rates per fraction. … READ MORE …

SBRT has equivalent toxicity when given with 5 and 12 treatments

Data reported at the recent Genitourinary Cancers Symposium have shown that the toxicities associated with stereotactic body radiation therapy (SBRT) are acceptable and similar whether the radiation is give as 5 or 12 doses. … READ MORE …

Hypofractionated radiation therapy with IMRT: same results in less time

The largest-yet randomized clinical trial comparing hypofractionated (fewer treatments or fractions) to normally fractionated intensity-modulated radiation therapy (IMRT) has proved that oncological outcomes and late-term toxicities were the same for both treatment schedules. … READ MORE …

The multi-factorial nature of SBRT safety

In a previous article, we looked at the experimental use of extreme hypofractionated radiation therapy (SBRT or SABR) to treat high-risk patients. Here, we take a closer look at an early (Phase I/II) safety study by Bauman et al. that shows why radiation safety is more complicated than just setting the treatment dose. … READ MORE …

Hypofractionation of radiation therapy in treatment of localized prostate cancer

Many readers may be interested in reading an editorial just published in the Journal of Clinical Oncology that deals with “hypofractionation” (giving fewer doses of radiation therapy at higher dose levels) in treatment of localized prostate cancer. … READ MORE …

WSJ questions value of proton beam radiation therapy

Advocates for proton beam radiation therapy (PBRT) are not going to be enamored of the article in the Wall Street Journal (WSJ) on the cost/benefit ratio of this form of treatment for localized prostate cancer.

How much hypofractionated IMRT is too much for localized prostate cancer?

A report to be presented at the upcoming meeting of the American Society for Radiation Oncology (ASTRO) offers 5-year outcome data from a trial comparing conventional intensity-modulated radiation therapy (IMRT) to the more recently developed hypofractionated IMRT for men with localized prostate cancer. … READ MORE …

Short-course radiation therapy for localized prostate cancer: two new trial results

Two new studies reported at the American Society for Radiation Oncology (ASTRO) annual meeting yesterday discuss the potential of shorter courses of “hypofractionated” radiation therapy in the treatment of localized prostate cancer. … READ MORE …

Prostate cancer news reports: Saturday, June 13, 2009

Today’s news reports include information on:

  • Outcomes comparing two types of radiation therapy
  • Outcomes of younger vs. older men after radical prostatectomy
  • The activity and safety of AZD0530 in CRPC … READ MORE …

Prostate cancer news reports: Friday, June 12, 2009

Todays news reports adddress:

  • Surgeon and hospital volume and outcomes to radical prostatectomy
  • Adverse events associated with the use of hypofractionated, dose-escalated, IMRT
  • Quality of sexual function after external beam radiation therapy
  • Percentage of positive biopsy cores and response to first-line hormone therapy … READ MORE …

Prostate cancer news reports: Tuesday, June 9, 2009

Today’s news reports deal with items on:

  • The mechanism of action of D,L-sulforaphane
  • Isolation of an active protein from the bitter melon plant
  • The potential of focal therapy for localized prostate cancer
  • Reconstruction of the lower urinary tract after radical prostatectomy
  • Hypofractionated intensity-modulated arc radiotherapy in  N1 prostate cancer … READ MORE …

The Tuesday news report: January 27, 2009

Today’s news deals with such items as:

  • Toxicities associated with hypofractionated, intensity-modulated radiation therapy
  • Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer
  • A Spanish review of photodynamic therapy
  • A proposed mechanism of action for the investigational drug Apoptone™ (HE3235) … READ MORE …